PNHInsights
Diagnosing and testing for PNH
Learn more about identifying and diagnosing your high-risk patients with the PNH Diagnostic Pathway. Targeting high-risk patients is important because early diagnosis drives effective PNH management and there is currently an effective treatment option available.
Click here to begin
View this presentation and receive a complimentary* Bronze PhRMA Card (a $25 value). Use this card to purchase medical and educational resources for your office.
*For US physicians only. Allowed in all states except DC, MA, ME, MN, and VT.
†Adapted from Parker , et al, Blood 2005.
References: 1. Parker C, Omine M, Richards S, et al; for the International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709. 2. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-1314.